This article is more than 5 years old. Information may no longer be current.
GIPR polymorphism linked to low BMD, fracture risk
Click Here to Manage Email Alerts
A functional polymorphism of the GIPR gene appears to be linked to low bone mineral density and fracture risk, according to study results.
This finding strengthens the established role of glucose-dependent insulinotropic peptide (GIP) in regulating bone density, the researchers said.
The prospective, comprehensive cohort study assessed a subgroup of 1,686 perimenopausal women enrolled in the Danish Osteoporosis Prevention Study. The participants agreed to DNA sampling and were successfully genotyped. The 10-year follow-up was completed by 1,424 participants, who were followed for longitudinal analyses while complying with their originally assigned treatment regimens.
The researchers utilized DXA to measure overall body and regional BMD at baseline, as well as at 5- and 10-year follow-up. Vertebral fractures were evaluated via X-ray at baseline and after 5 and 10 years, and incident fractures were revealed by participants via interview. The radiologic definition of vertebral fracture was the reduction of 20% or more of the anterior, posterior or central height of a vertebra as determined by X-ray.
The researchers chose the polymorphisms ms, rs10423928 and rs1800437, and these polymorphisms were genotyped using KASPar allelic discrimination (KBioscience).
At 10-year follow-up, the researchers found significantly lower femoral neck BMD in carriers of the minor frequency C-allele of rs1800437 (354 Gln) than in women with the major G-allele (P<.001). Additionally, they found an increased risk for non-vertebral fractures among women homozygous for the minor C allele (HR=1.6; 95% CI, 1-2.6).
The researchers said these findings support the concept of an interrelation between gastrointestinal hormones and bone density regulation.
“These findings further establish GIP as involved both in blood glucose and bone density regulation, supporting the existence of the suggested ‘entero-osseous axis,’” the researchers wrote.
Disclosure: Some of the researchers report being advisory board members or on the speakers’ bureau for Amgen, Eli Lilly and Merck.
Click Here to Manage Email Alerts